Your browser is no longer supported. Please, upgrade your browser.
Adagene Inc.
Index- P/E- EPS (ttm)-1.01 Insider Own- Shs Outstand42.67M Perf Week6.59%
Market Cap600.37M Forward P/E- EPS next Y-1.82 Insider Trans- Shs Float5.59M Perf Month-24.88%
Income-42.60M PEG- EPS next Q-0.41 Inst Own0.42% Short Float1.31% Perf Quarter-
Sales0.70M P/S857.67 EPS this Y-155.70% Inst Trans- Short Ratio0.39 Perf Half Y-
Book/sh- P/B- EPS next Y-34.80% ROA- Target Price- Perf Year-
Cash/sh1.76 P/C7.98 EPS next 5Y- ROE- 52W Range12.67 - 31.83 Perf YTD-53.08%
Dividend- P/FCF- EPS past 5Y- ROI53.10% 52W High-56.02% Beta-
Dividend %- Quick Ratio4.90 Sales past 5Y- Gross Margin- 52W Low10.50% ATR1.19
Employees198 Current Ratio4.90 Sales Q/Q-18.50% Oper. Margin- RSI (14)33.30 Volatility8.89% 8.05%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.00 Prev Close14.07
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume187.60K Price14.00
Recom1.70 SMA20-10.18% SMA50-30.97% SMA200-31.61% Volume42 Change-0.50%
Mar-08-21Initiated Morgan Stanley Overweight $34
Mar-08-21Initiated Jefferies Buy $33
Mar-08-21Initiated Goldman Buy $29
Apr-13-21 07:45AM  
Mar-31-21 07:45AM  
Mar-29-21 07:45AM  
Mar-16-21 08:05AM  
Feb-11-21 10:08AM  
Feb-09-21 05:18PM  
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. Its products include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase Ib clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in preclinical stage used in the treatment of cancers; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of metastatic solid tumors. The company was founded in 2011 and is headquartered in Suzhou, China.